Modality
Bispecific Ab
MOA
EGFRi
Target
JAK2
Pathway
Checkpoint
Urothelial CaFSGSNMOSD
Development Pipeline
Preclinical
Aug 2021
→ May 2025
PreclinicalCurrent
NCT05261603
2,989 pts·Urothelial Ca
2021-08→2025-05·Not yet recruiting
2,989 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-05-1710mo agoInterim· Urothelial Ca
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
Preclinical
Not yet…
Catalysts
Interim
2025-05-17 · 10mo ago
Urothelial Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05261603 | Preclinical | Urothelial Ca | Not yet recr... | 2989 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| Mavuratamab | Blueprint Medicines | NDA/BLA | BET | |
| Bemaderotide | Revolution Medicines | Phase 3 | BCL-2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 |